Literature DB >> 20615826

Controversies on the management of clinical situations with low therapeutic effectiveness in oncology.

José Expósito1, Juan José Bretón, Carmen Domínguez, Joana Pons.   

Abstract

Clinical scenarios associated with low therapeutic effectiveness (LTE) are especially complex and highly relevant in oncology. The objective was to test a methodological framework for creating consensual clinical recommendations for routine practice. The study was in three phases from Mars 2006 to January 2008: 1) Definition of LTE situations; 2) Preparation by 10 experts of a panel of LTE situations in cancers of breast, lung, head and neck, colon and rectum and brain; and 3) Development of a consensus on each situation and its optimal treatment by gathering agreement and disagreements (two-round Delphi method) from 68 practicing oncologists in Andalusian Community. Three major and three minor criteria were established for an LTE situation, defined when at least one major or two minor criteria were met. The expert group proposed 48 possible LTE clinical scenarios for breast (n = 7), lung (10), brain (11), head and neck (11) and colorectal cancers (9). Sixty-eight oncologists agreed to participate in the study; the response rate was 79% (from 34 medical and 17 radiation oncologists) In the first round (definition), maximum agreement was obtained with the LTE definition of 10 of the 48 scenarios; in the second round (treatment options), maximum agreement was obtained on the treatment of 3 of these 10 scenarios. Oncologists reached low levels of agreement on the definition of an LTE situation and on its treatment recommendations. This study proposes an approach to the improvement of cancer management in situations of high uncertainty.

Entities:  

Mesh:

Year:  2010        PMID: 20615826     DOI: 10.1007/s12094-010-0542-4

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  19 in total

1.  Pharmacoeconomics of Cancer Therapy.

Authors: 
Journal:  Cancer Control       Date:  1998-10       Impact factor: 3.302

2.  Developing a system to assess the quality of cancer care: ASCO's national initiative on cancer care quality.

Authors:  Eric C Schneider; Jennifer L Malin; Katherine L Kahn; Ezekiel J Emanuel; Arnold M Epstein
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

3.  Analysis of clinical decision-making in multi-disciplinary cancer teams.

Authors:  J M Blazeby; L Wilson; C Metcalfe; J Nicklin; R English; J L Donovan
Journal:  Ann Oncol       Date:  2005-12-01       Impact factor: 32.976

Review 4.  Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis.

Authors:  T J Smith; B E Hillner; C E Desch
Journal:  J Natl Cancer Inst       Date:  1993-09-15       Impact factor: 13.506

5.  Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.

Authors:  Paolo Maione; Francesco Perrone; Ciro Gallo; Luigi Manzione; FrancoVito Piantedosi; Santi Barbera; Silvio Cigolari; Francesco Rosetti; Elena Piazza; Sergio Federico Robbiati; Oscar Bertetto; Silvia Novello; Maria Rita Migliorino; Adolfo Favaretto; Mario Spatafora; Francesco Ferraù; Luciano Frontini; Alessandra Bearz; Lazzaro Repetto; Cesare Gridelli; Emiddio Barletta; Maria Luisa Barzelloni; Rosario Vincenzo Iaffaioli; Ermelinda De Maio; Massimo Di Maio; Gianfranco De Feo; Giuseppe Sigoriello; Paolo Chiodini; Angela Cioffi; Vincenzo Guardasole; Valentina Angelini; Antonio Rossi; Domenico Bilancia; Domenico Germano; Alfredo Lamberti; Vittorio Pontillo; Luigi Brancaccio; Francesco Renda; Francesco Romano; Gabriella Esani; Anna Gambaro; Orazio Vinante; Giuseppe Azzarello; Maurizia Clerici; Roberto Bollina; Paolo Belloni; Mirella Sannicolò; Libero Ciuffreda; Giuseppe Parello; Mary Cabiddu; Cosimo Sacco; Angela Sibau; Gianfranco Porcile; Federico Castiglione; Oliviero Ostellino; Silvio Monfardini; Micaela Stefani; Giorgio Scagliotti; Giovanni Selvaggi; Filippo De Marinis; Olga Martelli; Giampietro Gasparini; Alessandro Morabito; Domenico Gattuso; Giuseppe Colucci; Domenico Galetta; Francesco Giotta; Vittorio Gebbia; Nicola Borsellino; Antonio Testa; Emilia Malaponte; Matteo A Capuano; Michele Angiolillo; Francesco Sollitto; Umberto Tirelli; Simona Spazzapan; Vincenzo Adamo; Giuseppe Altavilla; Antonio Scimone; Maria Raffaella Hopps; Francesco Tartamella; Giovanni Pietro Ianniello; Vincenza Tinessa; Giuseppe Failla; Roberto Bordonaro; Nicola Gebbia; Maria Rosaria Valerio; Modesto D'Aprile; Enzo Veltri; Maurizio Tonato; Samir Darwish; Sante Romito; Francesco Carrozza; Sandro Barni; Antonio Ardizzoia; Giuliana Mara Corradini; Gianfranco Pavia; Mario Belli; Giuseppe Colantuoni; Enzo Galligioni; Orazio Caffo; Roberto Labianca; Antonello Quadri; Enrico Cortesi; Giuliana D'Auria; Sergio Fava; Anna Calcagno; Gino Luporini; M Cristina Locatelli; Francesco Di Costanzo; Silvia Gasperoni; Luciano Isa; Paola Candido; Fernando Gaion; Giovanni Palazzolo; Giuseppe Nettis; Anselmo Annamaria; Massimo Rinaldi; Massimo Lopez; Raffaella Felletti; Giorgio Bernabò Di Negro; Nestore Rossi; Antonio Calandriello; Luigi Maiorino; Rodolfo Mattioli; Alfredo Celano; Stefania Schiavon; Alfonso Illiano; Carlo Alberto Raucci; Michele Caruso; Paolo Foa; Giuseppe Tonini; Carlo Curcio; Marina Cazzaniga
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

Review 6.  College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants.

Authors:  M E Hammond; P L Fitzgibbons; C C Compton; D J Grignon; D L Page; L P Fielding; D Bostwick; T F Pajak
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

7.  FOLFOX3 in heavily pretreated patients with metastatic colorectal cancer.

Authors:  N Croles; C H Smorenburg; C J van Groeningen; G Giaccone; E Boven
Journal:  Neth J Med       Date:  2004 Jul-Aug       Impact factor: 1.422

8.  Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma.

Authors:  B E Hillner
Journal:  Eur J Cancer       Date:  1998-07       Impact factor: 9.162

Review 9.  Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon cancer.

Authors:  Kyle D Holen
Journal:  Cancer Invest       Date:  2006-02       Impact factor: 2.176

Review 10.  Quality of life measurement: bibliographic study of patient assessed health outcome measures.

Authors:  Andrew Garratt; Louise Schmidt; Anne Mackintosh; Ray Fitzpatrick
Journal:  BMJ       Date:  2002-06-15
View more
  1 in total

1.  KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting.

Authors:  Carlo Barone; Carmine Pinto; Nicola Normanno; Lorenzo Capussotti; Francesco Cognetti; Alfredo Falcone; Lorenzo Mantovani
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.